Companies eye cannabis investments

Companies eye cannabis investments

A presentation screen shows the properties of marijuana during a briefing at Chaophraya Abhaibhubejhr Hospital in Prachin Buri on July 5. (Photo by Patipat Janthong)
A presentation screen shows the properties of marijuana during a briefing at Chaophraya Abhaibhubejhr Hospital in Prachin Buri on July 5. (Photo by Patipat Janthong)

The government has removed cannabis and hemp extracts from its narcotics list, officials said on Monday, the latest effort to promote the development of marijuana products for medical purposes.

Thailand, which has a tradition of using cannabis to relieve pain and fatigue, legalised marijuana for medical use and research last year to help boost agricultural income.

"The intention is to allow extracts to be used in medicine, cosmetics and food and support hemp as a cash crop," Tares Krassanairawiwong, secretary-general of the Food and Drug Administration, told reporters, adding that hemp seed and oil would also be exempt.

So far, only hospitals and research facilities are allowed to apply for licences to develop medical extracts from cannabis, but businesses see an opportunity.

Ishaan Shah, from the billionaire Shah family, founded the Ganja Group in Bangkok and plans to supply medical cannabis to the family's GP Group's pharmaceutical arm, Megalife Sciences Plc.

"We are working towards cannabidiol [CBD] extraction, that's our short-term goal," Shah told Reuters.

The local cannabis market is expected to reach $660 million by 2024, according to analysis firm Prohibition Partners.

Extracts from cannabis and hemp plants such as pure CBD, CBD-based products and products with THC content of less than 0.2%, the psychoactive ingredient in cannabis, were removed from the narcotics Category 5 schedule, the regulator said.

Licences are not yet available for businesses.

Category 5 drugs are punishable by up to 15 years in prison and fines of up to 1.5 million baht.

Early-stage venture capital fund manager, Expara, is aiming to raise 918 million ($30 million) by December this year to invest in cannabis-related technology, said managing director Douglas Abrams.

"We think the change in the regulatory environment is a leading indicator of fast growth in this new industry," he told Reuters.

Cannabis production, cultivation and sale is limited to licensed Thai producers for five years to protect the domestic industry, Mr Tares said, adding that it was reviewing regulations that would allow businesses to apply for permits.

Some 334 permits have been issued so far, mainly to hospitals and health agencies, according to the FDA website.

Thailand delivered its first patch of 10,000 bottles of cannabis oil extract to patients last month.


Do you like the content of this article?
COMMENT (6)

RCEP talks want India back

With India appearing to have exited the RCEP, negotiators remain committed to bringing the country back into the fold as an "indispensable" member of the deal.

06:41

Somkid concerned about exports amid global unease

Deputy Prime Minister Somkid Jatusripitak's top concerns for next year are exports and confidence amid global economic uncertainties.

06:31

REIC upbeat on impact of latest property tax perks

The recent property tax incentives are expected to help drain housing inventory by 2.4% in the final two months of the year...

06:11